Hormonal
Thyroid-stimulating hormone (TSH) directly promotes hepatic lipogenesis and cholesterol biosynthesis, worsening NAFLD and hypercholesterolemia, independent of its role in stimulating thyroid hormone production.
If you have high TSH levels, even if your T3/T4 are normal, it may contribute to fatty liver and high cholesterol. Treating hypothyroidism to normalize TSH might help improve these metabolic markers, although lifestyle changes remain the primary treatment for NAFLD.
Taken together, these foregoing studies suggest that TSH may worsen hypercholesterolemia by increasing cholesterol biosynthesis, reducing cholesterol clearance, lowering LDLR, and worsen NAFLD by increasing lipogenesis, respectively.
Why this rating
Based on animal models and in vitro studies; human data is observational or derived from thyroidectomized patients with complex hormone replacements.
Source
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
Rohit A. Sinha et al. · Thyroid · 2019
DOI 10.1089/thy.2018.0664
More from this paper
- Thyroid hormone receptor beta (THRβ) agonists and specific thyroid hormone metabolites (T2, T1AM) reduce hepatic lipid content and serum cholesterol in NAFLD and hypercholesterolemia models by stimulating fatty acid oxidation and cholesterol clearance without the cardiac side effects of natural thyroid hormones.Moderate
- Glucagon-Thyroid Hormone (T3) conjugates reduce liver fat and improve dyslipidemia in obesity models by targeting the liver specifically, avoiding the cardiac and skeletal side effects of systemic T3 therapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →